Abstract:Current understanding of iron-deficient heart failure is based on blood tests that are thought to reflect systemic iron stores, but the available evidence suggests greater complexity. The entry and egress of circulating iron is controlled by erythroblasts, which (in severe iron deficiency) will sacrifice erythropoiesis to supply iron to other organs, e.g. the heart. Marked hypoferraemia (typically with anaemia) can drive the depletion of cardiomyocyte iron, impairing contractile performance and explaining why a transferrin saturation < ≈15%–16% predicts the ability of intravenous iron to reduce the risk of major heart failure events in long-term trials (Type 1 iron-deficient heart failure). However, heart failure may be accompanied by intracellular iron depletion within skeletal muscle and cardiomyocytes, which is disproportionate to the findings of systemic iron biomarkers. Inflammation- and deconditioning-mediated skeletal muscle dysfunction—a primary cause of dyspnoea and exercise intolerance in patients with heart failure—is accompanied by intracellular skeletal myocyte iron depletion, which can be exacerbated by even mild hypoferraemia, explaining why symptoms and functional capacity improve following intravenous iron, regardless of baseline haemoglobin or changes in haemoglobin (Type 2 iron-deficient heart failure). Additionally, patients with advanced heart failure show myocardial iron depletion due to both diminished entry into and enhanced egress of iron from the myocardium; the changes in iron proteins in the cardiomyocytes of these patients are opposite to those expected from systemic iron deficiency. Nevertheless, iron supplementation can prevent ventricular remodelling and cardiomyopathy produced by experimental injury in the absence of systemic iron deficiency (Type 3 iron-deficient heart failure). These observations, taken collectively, support the possibility of three different mechanistic pathways for the development of iron-deficient heart failure: one that is driven through systemic iron depletion and impaired erythropoiesis and two that are characterized by disproportionate depletion of intracellular iron in skeletal and cardiac muscle. These mechanisms are not mutually exclusive, and all pathways may be operative at the same time or may occur sequentially in the same patients.

What problem does this paper attempt to address?

This paper attempts to address the mechanism of iron - deficient heart failure. Specifically, the authors explored how iron deficiency leads to heart failure through three different mechanistic pathways: 1. **Heart failure caused by systemic iron deficiency (Type 1 iron - deficient heart failure)**: - **Characteristics**: This type of iron deficiency is usually manifested as transferrin saturation (TSAT) lower than approximately 15% - 16% and is accompanied by anemia. - **Mechanism**: In severe systemic iron deficiency, erythropoiesis will be affected to preferentially supply iron to other organs, such as the heart. This will lead to a decrease in the iron content within cardiomyocytes, affecting their contractile function. Therefore, patients with TSAT lower than approximately 15% - 16% can significantly reduce the risk of heart failure events after receiving intravenous iron supplementation. 2. **Skeletal muscle iron deficiency caused by inflammation and deconditioning (Type 2 iron - deficient heart failure)**: - **Characteristics**: This type of iron deficiency is usually manifested as TSAT lower than approximately 20% and is accompanied by obvious dysfunction, but may have no or only mild anemia. - **Mechanism**: Heart failure patients are often accompanied by inflammation and deconditioning, which will lead to a decrease in the iron content within skeletal muscles. Even mild hypoferremia will exacerbate this iron deficiency, resulting in dyspnea and decreased exercise tolerance. Intravenous iron supplementation can rapidly improve symptoms, exercise tolerance, and functional capacity. 3. **Cardiomyocyte iron deficiency caused by advanced heart failure (Type 3 iron - deficient heart failure)**: - **Characteristics**: This type of iron deficiency is usually manifested as TSAT lower than approximately 20% and is accompanied by severe cardiac insufficiency, but may have no or only mild anemia. - **Mechanism**: The iron content within cardiomyocytes in patients with advanced heart failure is decreased because the ability of iron to enter cardiomyocytes is weakened and the ability of iron to be excreted from cardiomyocytes is enhanced. Even mild hypoferremia will exacerbate this iron deficiency, thus affecting the mitochondrial function and ATP production of cardiomyocytes. Although iron supplementation can produce cellular - level benefits, its clinical response has not been fully studied. In general, this paper aims to reveal the complex mechanisms of iron - deficient heart failure and proposes three different pathways, which may co - exist or occur sequentially in the same patient. This helps to better understand the role of iron deficiency in heart failure and provides a theoretical basis for future treatment strategies.

Identification of three mechanistic pathways for iron-deficient heart failure

Critical re‐evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure

Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology

[Iron and stable ischemic heart disease - lessons from heart failure]

Redefining Iron Deficiency in Patients With Chronic Heart Failure

Iron homeostasis, recycling and vulnerability in the stressed kidney: A neglected dimension of iron‐deficient heart failure

Iron-deficiency anemia reduces cardiac contraction by downregulating RyR2 channels and suppressing SERCA pump activity

Iron deficiency and supplementation in heart failure

Associations of iron deficiency with cardiac function, congestion, exercise capacity and prognosis in heart failure

Anemia and Iron Deficiency in Heart Failure — Clinical Update

The Effect of Iron Deficiency on Cardiac Function and Structure in Heart Failure with Reduced Ejection Fraction

Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction

Iron deficiency in myocardial ischaemia: molecular mechanisms and therapeutic perspectives

Iron Status in Chronic Heart Failure: Impact on Symptoms, Functional Class and Submaximal Exercise Capacity

Pre-emptive iron supplementation prevents myocardial iron deficiency and attenuates adverse remodelling after myocardial infarction

Blood Differential Gene Expression in Patients with Chronic Heart Failure and Systemic Iron Deficiency: Pathways Involved in Pathophysiology and Impact on Clinical Outcomes

IMPACT OF IRON DEFICIENCY ON CLINICAL,BIOCHEMICAL AND ECHOCARDIOGRAPHIC PARAMETERS IN HEART FAILURE PATIENTS

Iron Deficiency and Deranged Myocardial Energetics in Heart Failure

Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?

Iron homeostasis in the heart: Molecular mechanisms and pharmacological implications

Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis